Sherbrooke Equity AG
Sherbrooke Equity AG: SALUGEN AG NEW CLIENT

Sherbrooke Equity AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

SALUGEN AG NEW CLIENT

ZURICH, Switzerland, September 5, 2008 -- Sherbrooke Equity AG (WKN:A0F6LN)
is pleased to feature Salugen™ AG, a life sciences company based in San
Diego, California, as a valued member of it’s growing roster of carefully
selected value growth oriented companies. Salugen utilizes gene testing to
create nutritional supplements uniquely tailored to address specific
consumers health needs which range from reducing drug cravings for clients
in treatment centers to providing energy boosts in medical spas.  Their
patent-protected, clinically-tested products contain blends of essential
vitamins, minerals, and amino acids to help promote wellness 'from the
inside out.' Sherbrooke Equity AG will hold a total of 4,681,500 shares of
the Salugen AG.

'We believe that Salugen is the company of our future, as addiction, along
with other issues, run rampant in our communities, both here and abroad.
They can help to shed light on the problem and create solutions to these
issues in our lives,' said Lee Leblanc, Managing Director of Sherbrooke
Equity AG.

Salugen provides customized treatments for people suffering from obesity;
and addictions to drugs, alcohol or nicotine. Gene testing allows Salugen
to help identify the addictive genes and create customized nutritional
formulas clinically proven to boost immune systems and reduce stress and
cravings. In doing so Salugen products help to flush out illnesses; and
help individuals to stop repetitive cycles of addiction.

Salugen also focuses on markets experiencing explosive growth—places where
people flock to find balance and tap into their optimal health. Their top
selling product line Spa Gen, is sold at leading day, resort and medical
spas; which are increasingly integrating 'wellness' programs into their
guest services. Accordingly, Spa Gen was recently featured in the New York
Times for its role in Las Vegas spas including the MGM-Grand, the Luxor and
the Bellagio. Likewise, Spa Gen—branded as FitGene—is sold at fitness,
sports and nutrition centers. These are all destinations frequented by
customers profoundly influenced by current trends towards lifestyle
improvement.

United States and European Union patents are being secured to launch
additional Salugen products currently in the pipeline. These products will
pinpoint specific needs in spa, dietary disorder, and addictive medical
markets. To this end, they have partnered with DNA Services of America to
develop a program for consumers of weight loss management products.


For Investor Relations Information Contact: 
Sherbrooke Equity AG
Louis Philippe Antunes +41793030125, 
lpantunes@sherbrookeequity.com 
http://www.sherbrookeequity.com/
04.09.2008  Financial News transmitted by DGAP
----------------------------------------------------------------------
 
Language:     English
Issuer:       Sherbrooke Equity AG
              Poststraße 3
              8001 Zürich
              Schweiz
Phone:        +41 (43) 443 70 73
Fax:          +41 (43) 443 70 77
E-mail:       info@3d-capital.ag
Internet:     www.3d-capital.ag
ISIN:         CH0022309576
WKN:          A0F6LN
Listed:       Freiverkehr in Berlin, Düsseldorf, Stuttgart; Entry Standard
              in Frankfurt
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------